- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01196078
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
29 juni 2015 uppdaterad av: Hoffmann-La Roche
A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer.
Patients will be randomized to receive either Tarceva (150 mg po daily) or vinorelbine (60 mg/m2 on days 1 and 8 of cycle 1 and 80 mg/m2 for the other 21 days cycles).
The anticipated time on study treatment is until disease progression.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
114
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Taipei, Taiwan
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
70 år och äldre (Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Adult patients, >=70 years of age
- Non-small cell lung cancer
- Naive to prior chemotherapy or specific immunotherapy
- Presence of at least 1 measurable lesion
Exclusion Criteria:
- Active non-controlled infection or disease
- CNS metastases
- Any other malignancies (other than adequately treated basal cell cancer of skin, or in situ cancer of the cervix)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
|
150 mg, orally once a day for up to 6 cycles of 21 days each
|
Aktiv komparator: 2
|
60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)
Tidsram: Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to 1 year
|
CR was defined as disappearance of all target lesions.
PR was defined as at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Participants experiencing either a CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) were classified as responders.
Participants with tumour assessment unevaluable were viewed as non-responders.
|
Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to 1 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Achieving Disease Control
Tidsram: Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to 1 year
|
Disease control was defined as achieving a best overall response of CR, PR, or stable disease (SD) according to RECIST criteria.
Participants with tumor assessment unevaluable were viewed as uncontrolled.
|
Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to 1 year
|
Duration of Response Among Participants Who Achieved Either a CR or PR
Tidsram: Screening, Day 1 of Cycles 3 and 5, every 4th cycle during post-study treatment, and every 3 cycles during follow-up
|
Duration of response was defined similarly for complete and partial responders.
Complete response lasted from the date the complete response was first recorded to the date on which progressive disease was first noted or date of death.
Partial response lasted from the date of partial response to the date of the first observation of progressive disease or date of death.
|
Screening, Day 1 of Cycles 3 and 5, every 4th cycle during post-study treatment, and every 3 cycles during follow-up
|
Percentage of Participants With Disease Progression
Tidsram: Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death
|
Progressive disease was defined using RECIST as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
|
Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death
|
Time to Disease Progression
Tidsram: Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death
|
Time to disease progression was defined as the interval between the day of randomization and the first documentation of progressive disease or death.
|
Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death
|
Overall Survival: Percentage of Participants With an Progressive Disease or Death
Tidsram: Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment
|
Overall survival was defined as the time from the date of randomization to the date of death.
Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.
Participants without follow-up assessment were censored at the day of last dose and participants with no postbaseline information were censored at the time of randomization.
Progressive disease was defined per RECIST as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
|
Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment
|
Overall Survival: Time to Event
Tidsram: Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment
|
Overall survival was defined as the time from the date of randomization to the date of death.
Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.
Participants without follow-up assessment were censored at the day of last dose and participants with no post baseline information were censored at the time of randomization.
Overall median time to event was assessed for the population that experienced an event.
|
Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment
|
Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT) Questionnaire
Tidsram: Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
|
The FACT Questionnaire contains 4 general and 1 lung cancer symptom-specific subscale, including Physical Well-Being (PWB), Social/family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and the 8-item Lung Cancer Subscale (LCS) that assess symptoms commonly reported by participants with lung cancer.
Each subscale was assessed by a five-point scale from 0 (not at all) to 4 (very much) to determine the quality of life.
PWB, SWB and FWB scores ranged from 0-28 and EWB scores ranged from 0-24.
LCS scores ranged from 0-36.
For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'.
For other subscales and questionnaires, the higher score represented 'Worsened'.
Missing data were replaced by the valid post-baseline assessment before.
The FACT-L score ranges from 0 to 136, with higher scores indicating better quality of life.
|
Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
|
Changes in Quality of Life as Measured by the FACT Questionnaire
Tidsram: Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
|
The FACT Questionnaire contains 4 general and 1 lung cancer symptom-specific subscale, including PWB, SWB, EWB, FWB, and the 8-item LCS that assess symptoms commonly reported by participants with lung cancer.
Each subscale was assessed by a five-point scale from 0 (not at all) to 4 (very much) to determine the quality of life.
PWB, SWB and FWB scores ranged from 0-28 and EWB scores ranged from 0-24.
LCS scores ranged from 0-36.
For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'.
For other subscales and questionnaires, the higher score represented 'Worsened'.
Missing data were replaced by the valid post-baseline assessment before.
For PWB, FWB, SWB, and EWB scores and disease-specific subscale score, response of down, up or no change were defined as score changes of less than or equal to (≤)2, greater than or equal to (≥)+2, or between these values.
|
Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
|
Percentage of Participants With Changes in Quality of Life as Measured by FACT Questionnaire Scores by Category of Change
Tidsram: Baseline and End of study
|
The FACT and the FACT-L contain 4 general and 1 lung cancer symptom-specific subscale, including PWB, SWB, EWB, FWB, and the 8-item LCS that assess symptoms commonly reported by participants with lung cancer.
For subscales of FWB and SWB, questionnaires of EWB, and additional concerns questions, the higher score represented 'Improved'.
For other subscales and questionnaires, the higher score represented Worsened'.
For PWB, FWB, SWB, and EWB scores and disease-specific subscale score, higher scores indicated a better outcome; a response of down, up, or no change was defined as a score change of ≤ -2 (score down), ≥ +2 (score up), or between these values.
|
Baseline and End of study
|
Changes in Quality of Life as Assessed by FACT-L (Lung Symptoms) Questionnaire
Tidsram: Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
|
The LCS consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition) rated on a five-point scale from 0 (not at all) to 4 (very much).
The LCS total score is the sum of the scores from the 7 items.
For clear thinking and good appetite, the higher score represented 'Improved'; for other subscales and questionnaires, the higher score represented 'Worsened'.
Missing data were replaced by the valid post-baseline assessment before.
The change of FACT-L subscore was the change from baseline to endpoint.
The LCS of FACT-L is an independently validated tool that measures the disease-related symptoms of lung cancer on an overall scale of 0 (most symptomatic) to 28 (asymptomatic).
|
Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End of study
|
Percentage of Participants With Changes in FACT-L (Lung Symptoms) by Category of Change
Tidsram: Baseline and End of study
|
The LCS consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition).
The LCS total score is the sum of the scores from the 7 items, each rated on a five-point scale from 0 (not at all) to 4 (very much).
For clear thinking and good appetite, the higher score represented 'Improved'; for other subscales and questionnaires, the higher score represented 'Worsened'.
For each FACT-L question, the response status was defined as down, up, or no change if the score at endpoint was smaller (score down), larger than (score up), or the same as (no change) that at baseline.
|
Baseline and End of study
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 februari 2007
Primärt slutförande (Faktisk)
1 december 2010
Avslutad studie (Faktisk)
1 december 2010
Studieregistreringsdatum
Först inskickad
3 september 2010
Först inskickad som uppfyllde QC-kriterierna
3 september 2010
Första postat (Uppskatta)
8 september 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
27 juli 2015
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 juni 2015
Senast verifierad
1 juni 2015
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Lungneoplasmer
- Karcinom, icke-småcellig lunga
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Proteinkinashämmare
- Erlotinib hydroklorid
- Vinorelbin
Andra studie-ID-nummer
- ML20322
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Icke-småcellig lungcancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande kutant T-cell non-Hodgkin lymfom | Steg I Kutant T-cell non-Hodgkin lymfom | Steg II Kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAvslutadLymfom, icke-Hodgkin | Lymfom: Non-Hodgkin | Lymfom: Icke-Hodgkin perifer T-cell | Lymfom: Non-Hodgkin kutant lymfom | Lymfom: Non-Hodgkin Diffus Stor B-cell | Lymfom: Non-Hodgkin follikulära / indolenta B-cell | Lymfom: Non-Hodgkin Mantle Cell | Lymfom: Non-Hodgkin Marginal Zone | Lymfom: Non-Hodgkin...Förenta staterna
-
Novartis PharmaceuticalsAvslutadMelanom | Trippel negativ bröstcancer | Anaplastisk sköldkörtelcancer | Andra fasta tumörer | Non-small Sell Lung Cancer (NSCLC)Förenta staterna, Italien, Spanien, Ungern, Taiwan, Tyskland, Nederländerna, Frankrike, Norge, Polen, Thailand, Libanon, Kalkon, Kanada
-
John ReneauAktiv, inte rekryterandeÅterkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Steg III kutant T-cell non-Hodgkin lymfom | Steg IV Kutant T-cell non-Hodgkin lymfom | Primärt kutant anaplastiskt storcelligt lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Lymfomatoid... och andra villkorFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Walter HanelAktiv, inte rekryterandeÅterkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Refraktärt anaplastiskt storcelligt lymfom | T-cell non-Hodgkin lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande transformerat non-Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant... och andra villkorFörenta staterna
-
Mayo ClinicHar inte rekryterat ännuIndolent B-cell non-Hodgkin lymfom | Återkommande indolent non-Hodgkin-lymfom | Refraktärt indolent non-Hodgkin-lymfom | Återkommande indolent B-cell non-Hodgkin lymfom | Refraktärt indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfomFörenta staterna
Kliniska prövningar på erlotinib [Tarceva]
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern... och andra samarbetspartnersAvslutad
-
PfizerAvslutadKarcinom, icke-småcellig lungaFörenta staterna
-
M.D. Anderson Cancer CenterAvslutadAvancerad cancerFörenta staterna
-
Merck Sharp & Dohme LLCAvslutad
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.AvslutadKarcinom, icke-småcellig lungaFörenta staterna
-
PharmaMarAvslutadAvancerade maligna solida tumörerSpanien, Förenta staterna
-
Tragara Pharmaceuticals, Inc.AvslutadÅterkommande icke småcellig lungcancerFörenta staterna
-
PfizerAvslutadIcke-småcellig lungcancerFörenta staterna, Korea, Republiken av, Storbritannien, Grekland, Slovakien, Frankrike, Belgien, Irland, Japan, Spanien, Kina, Sverige, Indien, Ungern, Schweiz, Ryska Federationen, Tyskland, Mexiko, Danmark, Österrike, Finland, Polen, Sydafri...
-
New Mexico Cancer Care AllianceAvslutadAvancerade solida tumörmaligniteterFörenta staterna
-
SCRI Development Innovations, LLCBayerAvslutadIcke-småcellig lungcancerFörenta staterna